Rejuvenation of BMSCs senescence by pharmacological enhancement of TFEB-mediated autophagy alleviates aged-related bone loss and extends lifespan in middle aged mice

Abstract

Bone marrow stromal/stem cells (BMSCs) are generally considered as common progenitors for both osteoblasts and adipocytes in the bone marrow, but show preferential differentiation into adipocytes rather than osteoblasts under aging, thus leading to senile osteoporosis. Accumulated evidences indicate that rejuvenation of BMSCs by autophagic enhancement delays bone aging. Here we synthetized and demonstrated a novel autophagy activator, CXM102 that could induce autophagy in aged BMSCs, resulting in rejuvenation and preferential differentiation into osteoblasts of BMSCs. Furthermore, CXM102 significantly stimulated bone anabolism, reduced marrow adipocytes, and delayed bone loss in middle-age male mice. Mechanistically, CXM102 promoted transcription factor EB (TFEB) nuclear translocation and favored osteoblasts formation both in vitro and in vivo. Moreover, CXM102 decreased serum levels of inflammation and reduced organ fibrosis, leading to a prolonger lifespan in male mice. Our results indicated that CXM102 could be used as an autophagy inducer to rejuvenate BMSCs and shed new lights on strategies for senile osteoporosis and healthyspan improvement.

References

[1] Krampera M, Le Blanc K. Mesenchymal stromal cells: putative microenvironmental modulators become cell therapy. Cell Stem Cell, 2021, 28: 1708-1725

[2] Zupan J et al. Age-related alterations and senescence of mesenchymal stromal cells: Implications for regenerative treatments of bones and joints. Mech. Ageing Dev., 2021, 198

[3] Cheng M, Yuan W, Moshaverinia A, Yu B. Rejuvenation of mesenchymal stem cells to ameliorate skeletal aging. Cells, 2023, 12: 998

[4] Qadir A et al. Senile Osteoporosis: the involvement of differentiation and senescence of bone marrow stromal cells. Int. J. Mol. Sci., 2020, 21: 349

[5] Liu ZZ et al. Autophagy receptor OPTN (optineurin) regulates mesenchymal stem cell fate and bone-fat balance during aging by clearing FABP3. Autophagy, 2021, 17: 2766-2782

[6] Yu B et al. PGC-1alpha controls skeletal stem cell fate and bone-fat balance in osteoporosis and skeletal aging by inducing TAZ. Cell Stem Cell, 2018, 23: 193-209.e195

[7] Li H et al. FOXP1 controls mesenchymal stem cell commitment and senescence during skeletal aging. J. Clin. Invest., 2017, 127: 1241-1253

[8] Wang Y et al. Alpha-ketoglutarate ameliorates age-related osteoporosis via regulating histone methylations. Nat. Commun., 2020, 11

[9] Picke, A. K. et al. Thy-1 (CD90) promotes bone formation and protects against obesity. Sci. Transl. Med. 10, eaao6806 (2018).

[10] Deng P et al. Loss of KDM4B exacerbates bone-fat imbalance and mesenchymal stromal cell exhaustion in skeletal aging. Cell Stem Cell, 2021, 28: 1057-1073.e1057

[11] Ye L et al. Histone demethylases KDM4B and KDM6B promotes osteogenic differentiation of human MSCs. Cell Stem Cell, 2012, 11: 50-61

[12] Cai GP et al. Alkbh1-mediated DNA N6-methyladenine modification regulates bone marrow mesenchymal stem cell fate during skeletal aging. Cell Prolif., 2022, 55

[13] Xiao Y et al. Splicing factor YBX1 regulates bone marrow stromal cell fate during aging. EMBO J., 2023, 9

[14] Wu, Y. et al. Mettl3-mediated m6A RNA methylation regulates the fate of bone marrow mesenchymal stem cells and osteoporosis. Nat. Commun. 9, 4772 (2018).

[15] Chen XD et al. Autophagy in fate determination of mesenchymal stem cells and bone remodeling. World J. Stem Cells, 2020, 12: 776-786

[16] Wang, J. et al. The role of autophagy in bone metabolism and clinical significance. Autophagy 19, 2409–2427 (2023).

[17] Yang R et al. Premature aging of skeletal stem/progenitor cells rather than osteoblasts causes bone loss with decreased mechanosensation. Bone Res., 2023, 11: 35

[18] Cai Y et al. The landscape of aging. Sci. China Life Sci., 2022, 65: 2354-2454

[19] Liu, H. et al. PTH regulates osteogenesis and suppresses adipogenesis through Zfp467 in a feed-forward, PTH1R-cyclic AMP-dependent manner. Elife 12, e83345 (2023).

[20] Zhang, J. et al. The effect of parathyroid hormone on osteogenesis is mediated partly by osteolectin. Proc. Natl. Acad. Sci. USA 118, e2026176118 (2021).

[21] Wu H, Xue Y, Zhang Y, Wang Y, Hou J. PTH1-34 promotes osteoblast formation through Beclin1-dependent autophagic activation. J. Bone Miner. Metab., 2021, 39: 572-582

[22] Fan Y et al. Parathyroid hormone directs bone marrow mesenchymal cell fate. Cell Metab., 2017, 25: 661-672

[23] Wein, M. N. & Kronenberg, H. M. Regulation of bone remodeling by parathyroid hormone. Cold Spring Harb. Perspect. Med. 8, a031237 (2018).

[24] Yang M et al. Parathyroid hormone shifts cell fate of a leptin receptor-marked stromal population from adipogenic to osteoblastic lineage. J. Bone Min. Res., 2019, 34: 1952-1963

[25] Aman Y et al. Autophagy in healthy aging and disease. Nat. Aging, 2021, 1: 634-650

[26] Yin, X. et al. Autophagy in bone homeostasis and the onset of osteoporosis. Bone Res. 7, 28 (2019).

[27] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: an expanding universe. Cell, 2023, 186: 243-278

[28] Mizushima N, Levine B. Autophagy in human diseases. N. Engl. J. Med, 2020, 383: 1564-1576

[29] Li X et al. Targeting autophagy in osteoporosis: from pathophysiology to potential therapy. Ageing Res. Rev., 2020, 62

[30] Onal M et al. Suppression of autophagy in osteocytes mimics skeletal aging. J. Biol. Chem., 2013, 288: 17432-17440

[31] Wu J et al. Rapamycin improves bone mass in high-turnover osteoporosis with iron accumulation through positive effects on osteogenesis and angiogenesis. Bone, 2019, 121: 16-28

[32] Ma Y et al. Autophagy controls mesenchymal stem cell properties and senescence during bone aging. Aging Cell, 2018, 17

[33] Partridge L, Fuentealba M, Kennedy BK. The quest to slow ageing through drug discovery. Nat. Rev. Drug Discov., 2020, 19: 513-532

[34] Zhang Y, Zhang J, Wang S. The role of rapamycin in healthspan extension via the delay of organ aging. Ageing Res. Rev., 2021, 70

[35] Sharp ZD, Strong R. Rapamycin, the only drug that has been consistently demonstrated to increase mammalian longevity. An update. Exp. Gerontol., 2023, 176

[36] Mannick, J. B. & Lamming, D. W. Targeting the biology of aging with mTOR inhibitors. Nat. Aging, 3, 642–660 (2023).

[37] Abokyi, S., Ghartey-Kwansah, G. & Tse, D. Y. TFEB is a central regulator of the aging process and age-related diseases. Ageing Res. Rev. 89, 101985 (2023).

[38] Tan A, Prasad R, Lee C, Jho EH. Past, present, and future perspectives of transcription factor EB (TFEB): mechanisms of regulation and association with disease. Cell Death Differ., 2022, 29: 1433-1449

[39] Yoneshima E et al. The transcription factor EB (TFEB) regulates osteoblast differentiation through ATF4/CHOP-dependent pathway. J. Cell Physiol., 2016, 231: 1321-1333

[40] Ferron M et al. A RANKL-PKCbeta-TFEB signaling cascade is necessary for lysosomal biogenesis in osteoclasts. Genes Dev., 2013, 27: 955-969

[41] Gibault F et al. Non-photoinduced biological properties of verteporfin. Curr. Med. Chem., 2016, 23: 1171-1184

[42] Wang G, Ge L, Liu T, Zheng Z, Chen L. The therapeutic potential of arctigenin against multiple human diseases: A mechanistic review. Phytomedicine, 2023, 110

[43] Shen S et al. Synthesis and biological evaluation of arctigenin ester and ether derivatives as activators of AMPK. Bioorg. Med. Chem., 2013, 21: 3882-3893

[44] Cheng YH, Dong JC, Bian Q. Small molecules for mesenchymal stem cell fate determination. World J. Stem Cells, 2019, 11: 1084-1103

[45] Weng Z et al. Mesenchymal stem/stromal cell senescence: hallmarks, mechanisms, and combating strategies. Stem Cells Transl. Med., 2022, 11: 356-371

[46] Carrageta DF, Freire-Brito L, Oliveira PF, Alves MG. Evaluation of human spermatozoa mitochondrial membrane potential using the JC-1 Dye. Curr. Protoc., 2022, 2: e531

[47] Perelman A et al. JC-1: alternative excitation wavelengths facilitate mitochondrial membrane potential cytometry. Cell Death Dis., 2012, 3

[48] Ballabio A, Bonifacino JS. Lysosomes as dynamic regulators of cell and organismal homeostasis. Nat. Rev. Mol. Cell Biol., 2019, 21: 101-118

[49] Puertollano R, Ferguson SM, Brugarolas J, Ballabio A. The complex relationship between TFEB transcription factor phosphorylation and subcellular localization. EMBO J., 2018, 37

[50] Qiu D et al. In vitro determination of osteo-adipogenic lineage choice of bone marrow stromal/stem cells (BMSCs). Methods X, 2024, 12

[51] Zhou BO, Yue R, Murphy MM, Peyer JG, Morrison SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell, 2014, 15: 154-168

[52] Shen B et al. A mechanosensitive peri-arteriolar niche for osteogenesis and lymphopoiesis. Nature, 2021, 591: 438-444

[53] Kaushik S et al. Autophagy and the hallmarks of aging. Ageing Res. Rev., 2021, 72

[54] Choi HK et al. Tsc1 Regulates the balance between osteoblast and adipocyte differentiation through autophagy/Notch1/β-Catenin cascade. J. Bone Miner. Res., 2018, 33: 2021-2034

[55] Ceccariglia S, Cargnoni A, Silini AR, Parolini O. Autophagy: a potential key contributor to the therapeutic action of mesenchymal stem cells. Autophagy, 2020, 16: 28-37

[56] Debnath J, Gammoh N, Ryan KM. Autophagy and autophagy-related pathways in cancer. Nat. Rev. Mol. Cell Biol., 2023, 24: 560-575

[57] Luo, G. et al. Verteporfin attenuates trauma-induced heterotopic ossification of Achilles tendon by inhibiting osteogenesis and angiogenesis involving YAP/β-catenin signaling. The FASEB Journal 37, e23057 (2023).

[58] Malik N et al. Induction of lysosomal and mitochondrial biogenesis by AMPK phosphorylation of FNIP1. Science, 2023, 380

[59] Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet, 2019, 393: 364-376

[60] Mo, C. et al. Single-cell transcriptomics of LepR-positive skeletal cells reveals heterogeneous stress-dependent stem and progenitor pools. The EMBO journal 41, e108415 (2021).

[61] Tikhonova AN et al. The bone marrow microenvironment at single-cell resolution. Nature, 2019, 569: 222-228

[62] Decker M et al. Leptin-receptor-expressing bone marrow stromal cells are myofibroblasts in primary myelofibrosis. Nat. Cell Biol., 2017, 19: 677-688

[63] Sarkaria SM et al. Systematic dissection of coordinated stromal remodeling identifies Sox10⁺ glial cells as a therapeutic target in myelofibrosis. Cell Stem Cell, 2023, 30: 832-850.e836

[64] Zhang H et al. The roles of bone remodeling in normal hematopoiesis and age-related hematological malignancies. Bone Res., 2023, 11: 15

[65] Lopez-Otin C, Blasco MA, Partridge L, Serrano M, Kroemer G. The hallmarks of aging. Cell, 2013, 153: 1194-1217

[66] Guo J et al. Aging and aging-related diseases: from molecular mechanisms to interventions and treatments. Signal Transduct. Target Ther., 2022, 7: 391

[67] Li X et al. Inflammation and aging: signaling pathways and intervention therapies. Signal Transduct. Target Ther., 2023, 8: 239

[68] Wang T, He C. TNF-α and IL-6: the link between immune and bone system. Curr. drug targets, 2020, 21: 213-227

[69] Okamoto, K. & Takayanagi, H. Osteoimmunology. Cold Spring Harb. Perspect. Med. 9, a031245 (2019).

[70] Tsukasaki M, Takayanagi H. Osteoimmunology: evolving concepts in bone-immune interactions in health and disease. Nat. Rev. Immunol., 2019, 19: 626-642

[71] Luo Z et al. Mechano growth factor (MGF) and transforming growth factor (TGF)-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model. Biomaterials, 2015, 52: 463-475

[72] Wang, Z., Wei, D. & Xiao, H. in Biological Aging: Methods and Protocols (ed T. O. Tollefsbol) 135-144 (Humana Press, 2013).

[73] Li H et al. Mechano-growth factor enhances differentiation of bone marrow-derived mesenchymal stem cells. Biotechnol. Lett., 2015, 37: 2341-2348

[74] Shukla SK, Dasgupta A, Mulder SE, Singh PK. Molecular and physiological evaluation of pancreatic cancer-induced Cachexia. Methods Mol. Biol., 2019, 1882: 321-333

Funding

Science and Technology Department of Guangxi Zhuang Autonomous (Guangxi Science and Technology Department)(Guike AD19245094)

Doctoral Foundation of Guangxi University of Chinese Medicine (XP018148).Guangxi Key Laboratory of Efficacy Study on Chinese Materia Medica, 2020 (20-065-38).